title: Epileptiform seizure after sertraline treatment in an adolescent experiencing obsessive-compulsive disorder and presenting a rare pharmacogenetic status.
authors.forename: Pierre
authors.initials: P
authors.lastname: Baumann
authors.forename: Rémy
authors.initials: R
authors.lastname: Barbe
authors.forename: Assia
authors.initials: A
authors.lastname: Vabre-Bogdalova
authors.forename: Encarni
authors.initials: E
authors.lastname: Garran
authors.forename: Séverine
authors.initials: S
authors.lastname: Crettol
authors.forename: Chin B
authors.initials: CB
authors.lastname: Eap
mesh_terms: D000293:Adolescent; D014150:Antipsychotic Agents / Q000009:adverse effects; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics / Q000378:metabolism*; D004359:Drug Therapy, Combination; D004827:Epilepsy / Q000139:chemically induced*; D005260:Female; D005838:Genotype; D006801:Humans; D007527:Isoenzymes / Q000378:metabolism; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy*; D010597:Pharmacogenetics; D010641:Phenotype; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D020280:Sertraline / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use
chemical_list: D014150:Antipsychotic Agents; D003577:Cytochrome P-450 Enzyme System; D007527:Isoenzymes; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline